S1 mRNA
Experimental viral mRNA-based vaccine.
General information
Experimental viral mRNA-based vaccine delivered in lipid nanoparticles.
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
|
BALB/c mice | 20.51 | Delivered in lipid nanoparticles. Elicited T follicular helper (Tfh), germinal center (GC) B, and plasma cell responses. Specific IgG and neutralizing antibodies were produced. Increased frequency of NF-α-producing CD45+CD4+ and IFN-γ- or IL-4-producing CD45+-CD8+ T cells, respectively. |
Aug/05/2020 |
